{
    "name": "sulfur hexafluoride",
    "comment": "Rx",
    "other_names": [
        "Lumason"
    ],
    "classes": [
        "Contrast Media",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/lumason-sulfur-hexafluoride-999971",
    "pregnancy": {
        "common": [
            "There are no data on use in pregnant women to inform any drug- associated risks; no adverse developmental outcomes were observed in animal reproduction studies with administration of sulfur hexafluoride lipid-type A microspheres in pregnant rats and rabbits during organogenesis at doses up to at least 10 and 20 times, respectively, the maximum human dose of 4.8 mL based on body surface area"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on presence in human milk, effects on breastfed infant, or effects on milk production; developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following administration of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres",
                "Most serious reactions occur within 30 minutes of administration",
                "Assess all patients for presence of any condition that precludes administration (see Contraindications)",
                "Always have cardiopulmonary resuscitation personnel and equipment readily available before administering contrast media, and monitor all patients during and following for adverse reactions",
                "Risk of cardiopulmonary reactions increased with unstable cardiopulmonary conditions (acute MI, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias)"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to product or components, including polyethylene glycol (PEG)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "For intravenous or intravesicular use only; do not administer by intra-arterial injection",
                "Serious cardiopulmonary reactions, including fatalities, reported (see Black Box Warnings)",
                "Rare anaphylactoid reactions (eg, skin erythema, rash, urticaria, flushing, throat tightness, dyspnea, anaphylactic shock) observed; may occur in patients with no history of prior exposure (see Contraindications)",
                "Risk of systemic embolization; in patients with right-to-left, bidirectional, or transient right-to-left cardiac shunts, some IV sulfur hexafluoride lipid-containing microspheres may bypass filtering by the lung and directly enter the arterial circulation; occlusion of microcirculation by these microspheres may result in tissue ischemia; assess for embolic phenomena following administration",
                "High ultrasound mechanical index values may cause microsphere cavitation or rupture and lead to ventricular arrhythmias; end-systolic triggering with high mechanical indices has been reported to cause ventricular arrhythmias"
            ],
            "specific": [
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "In postmarketing use, serious hypersensitivity reactions were observed during or shortly following sulfur hexafluoride lipid-containing microsphere administration",
                        "The reactions may include anaphylaxis, with manifestations that may include death, shock, bronchospasm, dyspnea, throat tightness, angioedema, edema (pharyngeal, palatal, mouth, peripheral, localized), swelling (face, eye, lip, tongue, upper airway), facial hypoesthesia, rash, urticaria, pruritus, flushing, and erythema",
                        "These reactions may occur in patients with no history of prior exposure to sulfur hexafluoride lipid-containing microspheres",
                        "Product contains PEG; there may be increased risk of serious reactions including death in patients with prior hypersensitivity reaction(s) to PEG",
                        "Clinically assess patients for prior hypersensitivity reactions to products containing PEG, such as certain colonoscopy bowel preparations and laxatives",
                        "Always have cardiopulmonary resuscitation personnel and equipment readily available prior to product administration and monitor all patients for hypersensitivity reactions"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": "0.9"
        },
        {
            "name": "Nausea",
            "percent": "0.6"
        },
        {
            "name": "Dysgeusia",
            "percent": "0.3"
        },
        {
            "name": "Injection site pain",
            "percent": "0.3"
        },
        {
            "name": "Chest discomfort",
            "percent": "0.3"
        },
        {
            "name": "Feeling hot",
            "percent": "0.3"
        },
        {
            "name": "Chest pain",
            "percent": "0.2"
        },
        {
            "name": "Injection site warmth",
            "percent": "0.2"
        },
        {
            "name": "Serious reactions",
            "percent": "30"
        },
        {
            "name": "typically within",
            "percent": null
        },
        {
            "name": "minutes of administration",
            "percent": null
        },
        {
            "name": "have been reported and include fatalities",
            "percent": null
        },
        {
            "name": "symptoms suggestive of anaphylactoid",
            "percent": null
        },
        {
            "name": "hypersensitivity",
            "percent": null
        },
        {
            "name": "arrhythmias",
            "percent": null
        },
        {
            "name": "and hypertensive episodes",
            "percent": null
        },
        {
            "name": "Risk for serious cardiopulmonary reactions may increase with unstable cardiopulmonary conditions",
            "percent": null
        },
        {
            "name": "acute MI",
            "percent": null
        },
        {
            "name": "acute coronary artery syndromes",
            "percent": null
        },
        {
            "name": "worsening or unstable congestive heart failure",
            "percent": null
        },
        {
            "name": "or serious ventricular arrhythmias",
            "percent": null
        }
    ]
}